Semaglutide And Kidneys & Trying To Target Just One Vertebra

The Chiropractic Forward Podcast: Evidence-based Chiropractic Advocacy

CF 340: Semaglutide And Kidneys & Trying To Target Just One Vertebra Today we’re going to talk about Semaglutide And Kidneys & Trying To Target Just One Vertebra But first, here’s that sweet sweet bumper music

Purchase Dr. Williams’s book, a perfect educational tool and chiropractic research reference for the daily practitioner, from the Amazon store TODAY!

OK, we are back and you have found the Chiropractic Forward Podcast where we are giving evidence-based chiropractic a little personality and making it profitable. We’re not the stuffy, elitist, pretentious kind of research. We’re research talk over a couple of beers. So grab you a bushel. I’m Dr. Jeff Williams and I’m your host for the Chiropractic Forward podcast. I’m so glad you’re spending your time with us learning together. Chiropractors – I’m hiring at my personal clinic. I need talent, ambition, smarts, personality, and easy to get along with associates. If this is you and Amarillo, TX is your speed, send me an email at [e-mail] If you haven’t yet I have a few things you should do.

• Go to Amazon and check our my book called The Remarkable Truth About Chiropractic: A Unique Journey Into The Research. It’s excellent resource for you and is categorized into sections so the information is easy to find and written in a way that is easy to understand for everyone. It’s on Amazon. That’s the Remarkable Truth About Chiropractic by Jeff Williams.
• Like our Chiropractic Forward Facebook page,
• Join our private Chiropractic Forward Facebook group, and then
• Review our podcast on wherever you listen to it
• Last thing real quick, we also have an evidence-based brochure and poster store at chiropracticforward.com

You have found yourself smack dab in the middle of Episode #340 Now if you missed last week’s episode, we talked about multivitamins effect on mortality and acupuncture effect on PTSD. Make sure you don’t miss that info. Keep up with the class.

On the personal end of things…..

I just got back from our MCM East Mastermind. Yes, Kevin Christie also has a MCM West Mastermind. Which is fine. We East members know who the OGs are, the real pioneers of the MCM Mastermind. I’m really not a pioneer at all. I just know the value of masterminds and when Dr. Christie asked me when he very first considered setting one up, I was in. Easy yes. It’s surprising to me that so many others are not easy yeses to be honest. So many folks are really hesitant to invest in themselves and their abilities.

I get it. I used to be as well. I was on an island. I was just working, keeping my head down and getting through the day every day. Week after week. It wasn’t until I was coaxed into my first mastermind that I figured it out. I found community. I found the potential to be so much better in the clinic and in business. That one was EXPENSIVE! That first mastermind cost $1,000/month plus the cost of staying at the Westin in Dallas every month with food and lots of drinks piled on top. It was worth it though.

I grew the clinic and I grew my abilities. And I grew my community.

Dr. Christies is around $8,000/year if I remember correctly. Then you have travel and hotels and meals and drinks but only once per quarter so 4 times per year. And it’s worth it. Each member can tell you where an idea they learned from a fellow Masterminder saved them over $8,000 per year and most have saved or grown much much much more than that. So, again, get yourself a mastermind, won’t you?/ The East Mastermind still has 2 seats open for 2025 and I believe the West Mastermind has 5 or so open. So get hold of Dr. Christie today if that’s where you’re headed with your profession. It’ll help. Then you can thank your Ol’ Uncle Jeffro later. .

Outside of that, we are still in the throws of replacing our nurse practitioner that will be leaving us in October. It’ll be good for all parties involved. The person we have on tap to come in is a long time friend and we can’t wait to make it work with her. Remember this; in 26 years of practice, every big change that we had in our clinic, even when we thought it was terrible and catastrophic, always always turned out to be the best for the clinic and for me. Every single time. I don’t fear change. I just don’t like the uncertainty that comes with change.

So the quicker I solve the problems that come with change, the sooner I have peace of mind and can proceed to the next thing on my list that day. That’s what I’m trying to accomplish with this.

Item #1 The first one this week is called, “Study: Semaglutide Lowered Chronic Kidney Disease–Related Risks” by Anna Bock and published in JAMA on June 21, 2024. That’s got some serious sizzle! Remember, the citations can be found at chiropracticforward.com under this episode. Bock A. Study: Semaglutide Lowered Chronic Kidney Disease–Related Risks. JAMA. 2024;332(3):188. doi:10.1001/jama.2024.10349

How They Did It

The randomized, double-blind, parallel-group, placebo-controlled FLOW trial compared the effects of semaglutide to placebo as an adjunct to standard of care on kidney outcomes for prevention of progression of renal impairment and risk of renal and cardiovascular (CV) mortality. The study enrolled 3,533 participants with type 2 diabetes and chronic kidney disease.

What They Found

Findings showed treatment with semaglutide 1mg reduced the risk of kidney-disease progression as well as cardiovascular and kidney death by 24% compared with placebo. Both the Chronic Kidney Disease and cardiovascular components of the composite endpoint contributed to the reduction in risk. Semaglutide was also found to be superior to placebo for the confirmatory secondary endpoints, which included annual rate of change in eGFR, time to occurrence of a major adverse cardiovascular event and time to occurrence of all-cause death.

Wrap It Up “We are very excited about the results from FLOW showing that semaglutide 1mg reduces the risk of kidney disease progression,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “Approximately 40% of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”

Item #2 The second one today is called, “Spinal Manipulative Therapy for Nonspecific Low Back Pain: Does Targeting a Specific Vertebral Level Make a Difference?: A Systematic Review With Meta-analysis” by Sorensen et al and published in Journal of Orthopedic and Sports Physical Therapy in August of 2023. Peter Westlund Sørensen, PT, MSc1, Casper Glissmann Nim, DC, PhD2,3,4, Erik Poulsen, DC, PhD1, Carsten Bogh Juhl, PT, PhD1,5 J Orthop Sports Phys Ther 2023;53(9):529-539. Epub: 28 July 2023. doi:10.2519/jospt.2023.11962

Why They Did It We aimed to examine whether targeting spinal manipulative therapy (SMT), by applying the intervention to a specific vertebral level, produces superior clinical outcomes than a nontargeted approach in patients with nonspecific low back pain.

How They Did It Systematic review with meta-analysis. LITERATURE SEARCH: MEDLINE, Embase, CENTRAL, CINAHL, Scopus, PEDro, and Index to Chiropractic Literature were searched up to May 31, 2023. Randomized controlled trials comparing targeted SMT (mobilization or manipulation) to a nontargeted approach in patients with nonspecific low back pain, and measuring the effects on pain intensity and patient-reported disability.

What They Found

• Ten randomized controlled trials
• There was moderate-certainty evidence of no difference between targeted SMT and a nontargeted approach for pain intensity at postintervention and at follow-up
• For patient-reported disability, there was moderate-certainty evidence of no difference at postintervention and at follow-up
• Adverse events were reported in 4 trials, and were minor and evenly distributed between groups.

Wrap It Up

Targeting a specific vertebral level when administering SMT for patients with nonspecific low back pain did not result in improved outcomes on pain intensity and patient-reported disability compared to a non-targeted approach. This is great news because there’s great research out there that shows us that we aren’t as specific as we like to think we are. We’re always moving more joint levels than we’re trying to move. So it’s all good. Alright, that’s it. Keep on keepin’ on. Keep changing our profession from your corner of the world. The world needs evidence-based, patient-centered practitioners driving the bus. The profession needs us in the ACA and involved in leadership of state associations. So quit griping about the profession if you’re doing nothing to make it better. Get active, get involved, and make it happen. Let’s get to the message. Same as it is every week.

Store Remember the evidence-informed brochures and posters at chiropracticforward.com.

Purchase Dr. Williams’s book, a perfect educational tool and chiropractic research reference for the daily practitioner, from the Amazon store TODAY!

The Message

I want you to know with absolute certainty that when Chiropractic is at its best, you can’t beat the risk vs reward ratio because spinal pain is primarily a movement-related pain and typically responds better to movement-related treatment rather than chemical treatments like pills and shots. When compared to the traditional medical model, research and clinical experience show us patients can get good to excellent results for headaches, neck pain, back pain, and joint pain to name just a few. It’s safe and cost-effective can decrease surgeries & disability and we do it through conservative, non-surgical means with minimal hassle to the patient. And, if the patient treats preventatively after initial recovery, we can usually keep it that way while raising the overall level of health!

Key Point: At the end of the day, patients should have the guarantee of having the best treatment that offers the least harm. When it comes to non-complicated musculoskeletal complaints…. That’s Chiropractic!

Contact Send us an email at dr dot williams at chiropracticforward.com and let us know what you think of our show and tell us your suggestions for future episodes. Feedback and constructive criticism is a blessing and so are subscribes and excellent reviews on podcast platforms. We know how this works by now. If you value something, you have to share it, interact with it, review it, talk about it from time to time, and actively hit a few buttons to support it here and there when asked. It really does make a big difference.

Connect We can’t wait to connect with you again next week. From the Chiropractic Forward Podcast flight deck, this is Dr. Jeff Williams saying upward, onward, and forward.

Website http://www.chiropracticforward.com

Social Media Links https://www.facebook.com/chiropracticforward/

Chiropractic Forward Podcast Facebook GROUP https://www.facebook.com/groups/1938461399501889/

Twitter https://twitter.com/Chiro_Forward

YouTube https://www.youtube.com/channel/UCtc-IrhlK19hWlhaOGld76Q

iTunes https://itunes.apple.com/us/podcast/chiropractic-forward-podcast-chiropractors-practicing/id1331554445?mt=2

Player FM Link https://player.fm/series/2291021

Stitcher: https://www.stitcher.com/podcast/the-chiropractic-forward-podcast-chiropractors-practicing-through

TuneIn https://tunein.com/podcasts/Health–Wellness-Podcasts/The-Chiropractic-Forward-Podcast-Chiropractors-Pr-p1089415/

About the Author & Host Dr. Jeff Williams – Fellow of the International Academy of Neuromusculoskeletal Medicine (FIANM) and Board Certified Diplomate of the American Board of Forensic Professionals (DABFP) – Chiropractor in Amarillo, TX, Chiropractic Advocate, Author, Entrepreneur, Educator, Businessman, Marketer, and Healthcare Blogger & Vlogger

The post Semaglutide And Kidneys & Trying To Target Just One Vertebra appeared first on Chiropractic Forward.